A Multi-Target Nitrogen-Fused Azole Drug Platform Derived from a Pyrazoline-Thiadiazole Moiety: In Vivo Antimicrobial Validation and Comprehensive Anticancer Investigation Supported by Computational Studies
Hagar S. El-Hema·Adel A.-H. Abdel-Rahman·Rasha A. Hashem·Modather F. Hussein·Ahmed T. Elhendawy·M. Gh. Abou Abed·Mohamed A. Hawata·Eman S. Nossier·Asmaa Saleh·Najla Altwaijry·Mariam M. Hassan
Background: Cancer patients are highly susceptible to microbial infections due to immune suppression, necessitating therapeutic strategies that integrate anticancer efficacy with effective antimicrobial intervention. Chalcone-derived nitrogen-fused heterocycles represent a promising platform for developing multi-target agents with relevance to antimicrobial drug delivery, particularly for localized infections. Methods: A series of chalcone-based pyrazoline-thiadiazole nitrogen-fused azole hybrid